Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 21;23(1):25.
doi: 10.3390/ijms23010025.

Molecular Mechanisms of Cardiac Amyloidosis

Yukihiro Saito  1 , Kazufumi Nakamura  2 , Hiroshi Ito  2
Affiliations
Review

Molecular Mechanisms of Cardiac Amyloidosis

Yukihiro Saito et al. Int J Mol Sci. .

Abstract

Cardiac involvement has a profound effect on the prognosis of patients with systemic amyloidosis. Therapeutic methods for suppressing the production of causative proteins have been developed for ATTR amyloidosis and AL amyloidosis, which show cardiac involvement, and the prognosis has been improved. However, a method for removing deposited amyloid has not been established. Methods for reducing cytotoxicity caused by amyloid deposition and amyloid precursor protein to protect cardiovascular cells are also needed. In this review, we outline the molecular mechanisms and treatments of cardiac amyloidosis.

Keywords: amyloid; cytotoxicity; immunoglobulin light chain; transthyretin.

PubMed Disclaimer

Conflict of interest statement

Kazufumi Nakamura and Hiroshi Ito received lecture fees from Pfizer Japan Inc., Tokyo, Japan, and Alnylam Pharmaceuticals Inc., Tokyo, Japan, outside the submitted work. Yukihiro Saito declares no conflict of interest.

Figures

Figure 1
Figure 1
Mechanisms of amyloidosis and treatments.
See this image and copyright information in PMC

References

    1. Merlini G., Bellotti V. Molecular mechanisms of amyloidosis. N. Engl. J. Med. 2003;349:583–596. doi: 10.1056/NEJMra023144. - DOI - PubMed
    1. Grogan M., Scott C.G., Kyle R.A., Zeldenrust S.R., Gertz M.A., Lin G., Klarich K.W., Miller W.L., Maleszewski J.J., Dispenzieri A. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J. Am. Coll. Cardiol. 2016;68:1014–1020. doi: 10.1016/j.jacc.2016.06.033. - DOI - PubMed
    1. Fontana M., Ćorović A., Scully P., Moon J.C. Myocardial Amyloidosis: The Exemplar Interstitial Disease. JACC Cardiovasc. Imaging. 2019;12:2345–2356. doi: 10.1016/j.jcmg.2019.06.023. - DOI - PubMed
    1. Kyle R.A., Linos A., Beard C.M., Linke R.P., Gertz M.A., O’Fallon W.M., Kurland L.T. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79:1817–1822. doi: 10.1182/blood.V79.7.1817.1817. - DOI - PubMed
    1. Madan S., Kumar S.K., Dispenzieri A., Lacy M.Q., Hayman S.R., Buadi F.K., Dingli D., Rajkumar S.V., Hogan W.J., Leung N., et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood. 2012;119:1117–1122. doi: 10.1182/blood-2011-07-370031. - DOI - PMC - PubMed